FDA approves Inveltys to treat post-operative inflammation and pain following ocular surgery.- Kala Therapeutics.

Kala Pharmaceuticals, Inc. announced that the FDA has approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.

Inveltys is the first twice-daily (BID) ocular corticosteroid approved for this indication. All other ocular steroids are only approved for four-times-a-day dosing. This more frequent dosing requirement can lead to issues for both doctors and patients. Corticosteroids are the foundation of therapy for post-ocular surgery care, with the key goal of controlling inflammation and pain which is caused by surgical trauma to the eye. The use of ocular steroids post-surgery is to achieve a rapid reduction of inflammation and to promote healing of the eye. Therefore, ensuring close adherence to the steroid regimen is a critical factor for physicians in the post-surgery care of the patient and eventual overall success of the procedure.